Ovid Therapeutics (OVID) Current Deferred Revenue (2020 - 2025)

Ovid Therapeutics (OVID) reported Current Deferred Revenue of $718000.0 for Q3 2025, little changed quarter-over-quarter from $718000.0 in Q2 2025.

Ovid Therapeutics (OVID) Current Deferred Revenue (2020 - 2025) Analysis & Trends

Ovid Therapeutics has reported Current Deferred Revenue for 2 years, with the latest figure at $718000.0 in Q3 2025.

For the quarter ending Q3 2025, Current Deferred Revenue changed N/A year-over-year to $718000.0; the trailing twelve-month figure through Sep 2025 stood at $718000.0 (changed N/A YoY), and the FY2020 full-year result was $2.2 million, changed N/A from the prior year.
Current Deferred Revenue for Q3 2025 stood at $718000.0, roughly flat from $718000.0 in the prior quarter.
The five-year high for Current Deferred Revenue was $718000.0 in Q2 2025, with the low at $718000.0 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Ovid Therapeutics	311.83 Mn	156.31 Mn	-

Download Data